ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v10i4.771ppharm-210Research ArticleДИСКУССИОННЫЕ ВОПРОСЫ ФАРМАКОТЕРАПИИDEBATABLE ISSUES OF PHARMACOTHERAPYКЛИНИЧЕСКИЙ СЛУЧАЙ ПРИМЕНЕНИЯ ТОЦИЛИЗУМАБА У ПАЦИЕНТКИ С СИСТЕМНЫМ ЮВЕНИЛЬНЫМ ИДИОПАТИЧЕСКИМ АРТРИТОМCLINICAL CASE OF TOCILIZUMAB THERAPY IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITISМитенкоЕ. В.AlexeevaE. I.

PhD, Professor, head of the rheumatology department at the Scientific Center of Children’s Health

АлексееваЕ. И.AlexeevaE. I.

доктор медицинских наук, профессор, заведующая ревматологическим отделением Научного центраздоровья детей РАМН

alekatya@ya.ruДенисоваР. В.DenisovaR. V.СлепцоваТ. В.SleptsovaT. V.Научный центр здоровья детей РАМН, Москва, Российская ФедерацияРоссияScientific Center of Children’s Health, Moscow The First Sechenov Moscow State Medical UniversityRussian FederationНаучный центр здоровья детей РАМН, Москва Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Center of Children’s Health, Moscow, Russian Federation The First Sechenov Moscow State Medical University, Russian FederationRussian FederationНаучный центр здоровья детей РАМН, Москва, Российская ФедерацияРоссияScientific Center of Children’s Health, Moscow, Russian FederationRussian Federation201314082013104Педиатрическая фармакология154158Copyright © Митенко Е.В., Алексеева Е.И., Денисова Р.В., Слепцова Т.В., 20132013Митенко Е.В., Алексеева Е.И., Денисова Р.В., Слепцова Т.В.Alexeeva E.I., Alexeeva E.I., Denisova R.V., Sleptsova T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/210

The article presents a case of successful application of a monoclonal antibodies drug to interleukin 6 receptors (tocilizumab) at severe systemic juvenile idiopathic arthritis with the development of secondary hemophagocytic syndrome. Tocilizumab treatment secured a decrease in clinical and laboratory parameters of the disease activity, life quality improvement, systemic juvenile idiopathic arthritis and hemophagocytic syndrome remission and allowed avoiding the per os prescription of glucocorticoids.

детисистемный ювенильный идиопатический артритсиндром активации макрофаговтоцилизумабchildrensystemic juvenile idiopathic arthritishemophagocytic syndrometocilizumabReferencesCassidy J. T., Petty R. E., Laxer R. M., Lindsley C. B. Textbook of pediatric rheumatology. 6th ed. Saunders Elsevier, Philadelphia. 2010. Р. 794.Cassidy J. T., Petty R. E., Laxer R. M., Lindsley C. B. Textbook of pediatric rheumatology. 6th ed. Saunders Elsevier, Philadelphia, 2010. 794 p.Алексеева Е. И., Валиева С. И., Бзарова Т. М. Эффективность и безопасность повторных курсов лечения ритуксимабом тяжелого рефрактерного ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2009; 8 (5): 14–25.Alekseeva E. I., Valieva S. I., Bzarova T. M. Voprosy sovremennoi pediatrii = Current pediatrics. 2009; 8 (5): 14–25.Бзарова Т. М., Алексеева Е. И., Петеркова В. А. Роль факторов болезни и факторов противоревматической терапии в развитии низкорослости у детей, страдающих ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2006; 5 (5): 13–18.Bzarova T. M., Alekseeva E. I., Peterkova V. A. Voprosy sovremennoi pediatrii = Current pediatrics. 2006; 5 (5): 13–18.Kelly A., Ramanan A. V. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol. 2007; 19: 477–81.Kelly A., Ramanan A. V. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr. Opin. Rheumatol. 2007; 19: 477–81.Cortis E., Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr Suppl. 2006; 95: 38–41.Cortis E., Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr Suppl. 2006; 95: 38–41.Veldhuis G. J., Willemse P. H. B., Sleijfer D. T. et al. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J Clin Oncol. 1995; 13: 2585–2593.Veldhuis G. J., Willemse P. H. B., Sleijfer D. T. et al. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J. Clin. Oncol. 1995; 13: 2585–2593.Rothwell N. J., Busbridge N. J., Lefeuvre R. A., Hardwick A. J. Interleukin-6 is a centrally acting endogenous pyrogen in the rat. Can J Physiol Pharmacol. 1991; 69: 1465–1469.Rothwell N. J., Busbridge N. J., Lefeuvre R. A., Hardwick A. J. Interleukin-6 is a centrally acting endogenous pyrogen in the rat. Can J. Physiol. Pharmacol. 1991; 69: 1465–1469.Castell J. V., Gomez-Lechon M. J., David M. et al. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 1988; 232: 347–350.Castell J. V., Gomez-Lechon M. J., David M. et al. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 1988; 232: 347–350.Nemeth E., Rivera S., Gabayan V. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113: 1271–1276.Nemeth E., Rivera S., Gabayan V. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 2004; 113: 1271–1276.Ikebuchi K., Wong G. G., Clark S. C., Ihle J. N., Hirai Y., Ogawa M. Interleukin-6 enhancement of interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci. USA. 1987; 84: 9035–9039.Ikebuchi K., Wong G. G., Clark S. C., Ihle J. N., Hirai Y., Ogawa M. Interleukin-6 enhancement of interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc. Natl. Acad. Sci. USA. 1987; 84: 9035–9039.Kimura H., Ishibashi T., Uchida T., Maruyama Y., Friese P., Burstein S. A. Interleukin 6 is a differentiation factor for human megakaryocytes in vitro. Eur J Immunol. 1990; 20: 1927–1931.Kimura H., Ishibashi T., Uchida T., Maruyama Y., Friese P., Burstein S. A. Interleukin 6 is a differentiation factor for human megakaryocytes in vitro. Eur. J. Immunol. 1990; 20: 1927–1931.Tsigos C., Papankolaou D. A., Defensor R., Mitsiadis C. S., Kyrou I., Chrousos G. P. Dose-effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology. 1997; 66: 54–62.Tsigos C., Papankolaou D. A., Defensor R., Mitsiadis C. S., Kyrou I., Chrousos G. P. Dose-effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology. 1997; 66: 54–62.Heliovaara M. K., Teppo A. M., Karonen S. L., Tuominen J. A., Ebeling P. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes Metab. 2005; 7: 729–736.Heliovaara M. K., Teppo A. M., Karonen S. L., Tuominen J. A., Ebeling P. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes Metab. 2005; 7: 729–736.Cutolo M., Straub R. H. Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction. Autoimmun Rev. 2008; 7: 223–228.Cutolo M., Straub R. H. Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction. Autoimmun Rev. 2008; 7: 223–228.Nishimoto N., Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol. 2008; 181: 151–160.Nishimoto N., Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol. 2008; 181: 151–160.European Medicines Agency. RoActemra (tocilizumab): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandoes/PDFs/EPAR/RoActemra/H-955-PI-en.pdf [accessed 2009 Mar 23].European Medicines Agency. RoActemra (tocilizumab): summary of product characteristics [online]. Available at: http://www.emea.europa.eu/humandoes/PDFs/EPAR/RoActemra/H-955-PI-en.pdf [accessed 2009 Mar 23].Chugai Pharmactutical Co. Actemra, a humanized antihuman IL-6 receptor monoclonal antibody obtained approval for indications of rheumatoid arthritis, polyarticular-course juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis [media release]. Available from: http://www.chugai-pharm.co.jp [accessed 2008 Sep 24].Chugai Pharmactutical Co. Actemra, a humanized antihuman IL-6 receptor monoclonal antibody obtained approval for indications of rheumatoid arthritis, polyarticular-course juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis [media release]. Available at: http://www.chugai-pharm.co.jp [accessed 2008 Sep 24].Imagawa T., Ozawa R., Miyamae T. et al. Efficacy and safety in 48-week treatment of tocilizumab in children with polyaticular course JIA with polyarticlar or olygoarticular onset. Ann Rheum Dis. 2007; 66 (Suppl. II): 550.Imagawa T., Ozawa R., Miyamae T. et al. Efficacy and safety in 48-week treatment of tocilizumab in children with polyaticular course JIA with polyarticlar or olygoarticular onset. Ann. Rheum. Dis. 2007; 66 (Suppl. II): 550.Yokota S., Imagawa T., Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis [SAT0536]. Ann Rheum Dis. 2009; 68 (Suppl. 3): 715.Yokota S., Imagawa T., Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis [SAT0536]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 715.Inaba Y., Aoki C., Ozawa R. Radiologic evaluation of large joints during tocilizumab treatment in children with systemic juvenile idiopathic arthritis [SAT0555]. Ann Rheum Dis. 2009; 68 (Suppl. 3): 720.Inaba Y., Aoki C., Ozawa R. Radiologic evaluation of large joints during tocilizumab treatment in children with systemic juvenile idiopathic arthritis [SAT0555]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 720.Yokota S., Imagawa T., Mori M. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371: 998–1006.Yokota S., Imagawa T., Mori M. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371: 998–1006.Yokota S., Miyamae T., Imagawa T. et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52: 818–825.Yokota S., Miyamae T., Imagawa T. et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52: 818–825.Aoki C., Inaba Y., Ozawa R. Effects of tocilizumab on radiological findings in polyarticular juvenile idiopathic arthritis [OP-0145]. Ann Rheum Dis. 2009; 68 (Suppl. 3): 118.Aoki C., Inaba Y., Ozawa R. Effects of tocilizumab on radiological findings in polyarticular juvenile idiopathic arthritis [OP-0145]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 118.Quartier P., Maire D., Souabni L. Efficacy and safety of tocilizumab in systemic onset juvenile idiopathic arthritis in french centers [FRI0462]. Ann Rheum Dis. 2009; 68 (Suppl. 3): 506.Quartier P., Maire D., Souabni L. Efficacy and safety of tocilizumab in systemic onset juvenile idiopathic arthritis in french centers [FRI0462]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 506.Kaneko U., Imagawa T., Kishi T. Discrepancy between progression of joint damage and improvement of systemic inflammation in patients with systemic-onset juvenile idiopathic arthritis treated with tocilizumab [SAT0548]. Ann Rheum Dis. 2009; 68 (Suppl. 3): 719.Kaneko U., Imagawa T., Kishi T. Discrepancy between progression of joint damage and improvement of systemic inflammation in patients with systemic-onset juvenile idiopathic arthritis treated with tocilizumab [SAT0548]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 719.Алексеева Е. И., Денисова Р. В., Валиева С. И. и др. Эффектив ность и безопасность тоцилизумаба у больных тяжелым системным ювенильным идиопатическим артритом. Вопросы современной педиатрии. 2011; 10 (3): 24–31.Alekseeva E. I., Denisova R. V., Valieva S. I. et al. Voprosy sovremennoi pediatrii = Current pediatrics. 2011; 10 (3): 24–31.Баранов А. А., Алексеева Е. И., Денисова Р. В., Валиева С. И., Бзарова Т. М., Исаева К. Б., Слепцова Т. В., Митенко Е. В., Чистякова Е. Г., Фетисова А. Н. Ретроспективный анализ эффективности и безопасности тоцилизумаба у больных тяжелым системным ювенильным идиопатическим артритом: 12 месяцев наблюдения. Вопросы современной педиатрии. 2013; 12 (2): 26–34.Baranov A. A., Alekseeva E. I., Denisova R. V., Valieva S. I., Bzarova T. M., Isaeva K. B., Sleptsova T. V., Mitenko E. V., Chistyakova E. G., Fetisova A. N. Voprosy sovremennoi pediatrii = Current pediatrics. 2013; 12 (2): 26–34.De Benedetti F., Brunner H., Ruperto N. et al. Efficacy and safety of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA): 12-week data from the phase 3 tender trial [OP0273]. Ann Rheum Dis. 2010; 69 (Suppl. 3): 146.De Benedetti F., Brunner H., Ruperto N. et al. Efficacy and safety of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA): 12-week data from the phase 3 tender trial [OP0273]. Ann. Rheum. Dis. 2010; 69 (Suppl. 3): 146.De Benedetti F., Brunner H., Ruperto N. et al. Efficacy and Safety of Tocilizumab (TCZ) in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA): TENDER 52-Week Data [OP0006]. Ann Rheum Dis. 2011; 70 (Suppl. 3): 67.De Benedetti F., Brunner H., Ruperto N. et al. Efficacy and Safety of Tocilizumab (TCZ) in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA): TENDER 52-Week Data [OP0006]. Ann. Rheum. Dis. 2011; 70 (Suppl. 3): 67.Намазова-Баранова Л.С. Научные исследования и инфраструктура платформы «Педиатрия». Педиатрическая фармакология. 2012; 9 (4): 15–24.Namazova-Baranova L.S. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9 (4): 15–24.

The authors declare that there are no conflicts of interest present.